05/20/2026
WPS Oncology Related LCD Updates
New Policy Updates
May 2026 Local Coverage Determination (LCD) and Billing and Coding Article Updates
We updated the following Local Coverage Determinations (LCDs) and Billing and Coding Articles for May 2026. The full article on our website details additional information on these updates.
Please note: Our LCDs and Billing and Coding/Coverage articles will reflect these changes on April 30, 2026
New Policies/Articles – We created no new policies/articles for May 2026.
Retired Policies/Articles – We retired no policies/articles for May 2026.
Revised Policies/Articles – We revised the following policies/articles for May 2026 – Effective as Indicated
- Billing and Coding: Botulinum Toxin Injections – Effective April 9, 2026
- Billing and Coding: Cervical Fusion – Effective April 9, 2026
- Billing and Coding: Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea – Effective April 9, 2026
- Billing and Coding: MolDx: Blueprint® Test – Effective April 1, 2026
- Billing and Coding: MolDx: Molecular Diagnostic Tests (MDT) – Effective April 1, 2026
- Billing and Coding: MolDx: Repeat Germline Testing – Effective April 1, 2026
- Billing and Coding: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) – Effective January 1, 2026
- Self-Administered Drug Exclusion List (SAD LIST) – Effective June 14, 2026